Skip to content

Author

Long Xu

We have 2 of 48 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Explainable machine learning for predicting grade ≥3 treatment-related adverse events in resectable non-small cell lung cancer receiving neoadjuvant chemoimmunotherapy: predominant contribution of hematologic toxicity

Background Neoadjuvant chemoimmunotherapy improves outcomes for resectable non-small cell lung cancer (NSCLC), but can cause severe treatment-related adverse events (TRAEs). Pretreatment models for predicting grade ≥3 TRAEs during neoadjuvant chemoimmunotherapy remain limited. This study aimed to develop and externally...

F. Zhi, Yun-Zeng Zhang, Teng-Fei Ge et al. · 0 citations
Open access Aug 2026

Multi‐Omics Integration Identifies a CDH3‐Associated Malignant Epithelial State and Immunosuppressive Niche to Predict Prognosis in Thymic Epithelial Tumors

CDH3 is defined as a biomarker and therapeutic target linking malignant epithelial plasticity to immunosuppressive niche formation and adverse clinical behavior in TETs.

Yuntao Feng, Jing-Yu Chen, Lang Xia et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.